阿尔茨海默病纵向研究中血液蛋白质水平的变化：澳大利亚衰老队列影像生物标志物与生活方式研究的结果
Altered levels of blood proteins in Alzheimer's disease longitudinal study: Results from Australian Imaging Biomarkers Lifestyle Study of Ageing cohort.
作者信息
Gupta Veer Bala, Hone Eugene, Pedrini Steve, Doecke James, O'Bryant Sid, James Ian, Bush Ashley I, Rowe Christopher C, Villemagne Victor L, Ames David, Masters Colin L, Martins Ralph N
机构信息
School of Medical Sciences, Edith Cowan University, Joondalup, Western Australia, Australia.
Co-operative Research Centre for Mental Health, Carlton, Victoria, Australia.
出版信息
Alzheimers Dement (Amst). 2017 Apr 23;8:60-72. doi: 10.1016/j.dadm.2017.04.003. eCollection 2017.
INTRODUCTION
A blood-based biomarker panel to identify individuals with preclinical Alzheimer's disease (AD) would be an inexpensive and accessible first step for routine testing.
METHODS
We analyzed 14 biomarkers that have previously been linked to AD in the Australian Imaging Biomarkers lifestyle longitudinal study of aging cohort.
RESULTS
Levels of apolipoprotein J (apoJ) were higher in AD individuals compared with healthy controls at baseline and 18 months ( = .0003) and chemokine-309 (I-309) were increased in AD patients compared to mild cognitive impaired individuals over 36 months ( = .0008).
DISCUSSION
These data suggest that apoJ may have potential in the context of use (COU) of AD diagnostics, I-309 may be specifically useful in the COU of identifying individuals at greatest risk for progressing toward AD. This work takes an initial step toward identifying blood biomarkers with potential use in the diagnosis and prognosis of AD and should be validated across other prospective cohorts.
引言
一个基于血液的生物标志物组合，用于识别患有临床前阿尔茨海默病（AD）的个体，将是进行常规检测的廉价且可及的第一步。
方法
在澳大利亚影像生物标志物与生活方式衰老队列纵向研究中，我们分析了14种先前已与AD相关联的生物标志物。
结果
在基线和18个月时，与健康对照相比，AD个体中的载脂蛋白J（apoJ）水平更高（P = .0003）；在36个月期间，与轻度认知障碍个体相比，AD患者中的趋化因子-309（I-309）增加（P = .0008）。
讨论
这些数据表明，apoJ在AD诊断的应用背景（COU）中可能具有潜力，I-309在识别进展为AD风险最高个体的COU中可能特别有用。这项工作朝着识别在AD诊断和预后中具有潜在用途的血液生物标志物迈出了第一步，并且应该在其他前瞻性队列中进行验证。
Zotero 插件